Table 3.

Clinical outcomes of anti-TNF treatment up to 4 years in patients with psoriatic arthritis. Frequencies of patients achieving a “good” EULAR response or HAQ improvement ≥ 0.5 from baseline (DHAQ) are given. Adalimumab (ADA), etanercept (ETN), and infliximab (IFX) are compared by chi-squared test. Except for p values, data are percentages.

	“Good” EULAR Response				ΔHAQ ≥ 0.5
	ADA	ETN	IFX	p	ADA	ETN	IFX	p
6 mos	59	70	71	0.13	49	57	46	0.12
1 yr	59	73	78	0.02	55	65	75	0.04
2 yrs	70	74	85	0.17	63	66	69	0.75
3 yrs	67	76	85	0.04	58	62	57	0.62
4 yrs	61	79	83	0.04	61	56	61	0.79

TNF: tumor necrosis factor; EULAR: European League Against Rheumatism; HAQ: Health Assessment Questionnaire.